BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32718089)

  • 21. Sappanone A inhibits RANKL-induced osteoclastogenesis in BMMs and prevents inflammation-mediated bone loss.
    Choo YY; Tran PT; Min BS; Kim O; Nguyen HD; Kwon SH; Lee JH
    Int Immunopharmacol; 2017 Nov; 52():230-237. PubMed ID: 28946117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
    Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Thymoquinone prevents RANKL-induced osteoclastogenesis activation and osteolysis in an in vivo model of inflammation by suppressing NF-KB and MAPK Signalling.
    Thummuri D; Jeengar MK; Shrivastava S; Nemani H; Ramavat RN; Chaudhari P; Naidu VG
    Pharmacol Res; 2015 Sep; 99():63-73. PubMed ID: 26022736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triterpenoids from Celastrus orbiculatus Thunb. inhibit RANKL-induced osteoclast formation and bone resorption via c-Fos signaling.
    Vu TO; Tran PT; Seo W; Lee JH; Min BS; Kim JA
    J Nat Med; 2021 Jan; 75(1):56-65. PubMed ID: 32779093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The prevention of latanoprost on osteoclastgenesis in vitro and lipopolysaccharide-induced murine calvaria osteolysis in vivo.
    Xu X; Yan Y; Liu Z; Qi J; Qian N; Zhou H; Zhou Q; Wang T; Huang P; Guo L; Jiang M; Deng L
    J Cell Biochem; 2018 Jun; 119(6):4680-4691. PubMed ID: 29274286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
    Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zanthoxylum bungeanum seed oil inhibits RANKL-induced osteoclastogenesis by suppressing ERK/c-JUN/NFATc1 pathway and regulating cell cycle arrest in RAW264.7 cells.
    He F; Luo S; Liu S; Wan S; Li J; Chen J; Zuo H; Pei X
    J Ethnopharmacol; 2022 May; 289():115094. PubMed ID: 35149133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
    Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
    Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
    Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
    Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Schisantherin A suppresses osteoclast formation and wear particle-induced osteolysis via modulating RANKL signaling pathways.
    He Y; Zhang Q; Shen Y; Chen X; Zhou F; Peng D
    Biochem Biophys Res Commun; 2014 Jul; 449(3):344-50. PubMed ID: 24845381
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
    Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
    Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel small molecule, NecroX-7, inhibits osteoclast differentiation by suppressing NF-κB activity and c-Fos expression.
    Kim HJ; Yoon KA; Lee MK; Kim SH; Lee IK; Kim SY
    Life Sci; 2012 Nov; 91(19-20):928-34. PubMed ID: 23000100
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibitory effects of melatonin on titanium particle-induced inflammatory bone resorption and osteoclastogenesis via suppression of NF-κB signaling.
    Ping Z; Wang Z; Shi J; Wang L; Guo X; Zhou W; Hu X; Wu X; Liu Y; Zhang W; Yang H; Xu Y; Gu Y; Geng D
    Acta Biomater; 2017 Oct; 62():362-371. PubMed ID: 28867647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fengshi Qutong capsule ameliorates bone destruction of experimental rheumatoid arthritis by inhibiting osteoclastogenesis.
    Li Y; Yang C; Jia K; Wang J; Wang J; Ming R; Xu T; Su X; Jing Y; Miao Y; Liu C; Lin N
    J Ethnopharmacol; 2022 Jan; 282():114602. PubMed ID: 34492323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.
    Joung YH; Darvin P; Kang DY; Sp N; Byun HJ; Lee CH; Lee HK; Yang YM
    PLoS One; 2016; 11(7):e0159891. PubMed ID: 27447722
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
    Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
    Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diarylheptanoid from Curcuma comosa Roxb. suppresses RANKL-induced osteoclast differentiation by decreasing NFATc1 and c-Fos expression via MAPK pathway.
    Chawalitpong S; Sornkaew N; Suksamrarn A; Palaga T
    Eur J Pharmacol; 2016 Oct; 788():351-359. PubMed ID: 27523282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.